Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 22,344 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTIVE Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating a Mat-Based Biometric Vibration System for Sleep and Daily Recovery

NCT07221318
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
Low-frequency whole-body vibration mat
Device
Lead sponsor
Florida International University
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia

NCT04139018
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Timolol Gel, Placebo Gel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Phase 1Phase 2 Interventional

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

NCT00911560
View directory record Official record
Conditions
Neuroblastoma
Interventions
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH, oral β-glucan
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 24, 2026, 10:15 AM EDT
Recruiting Phase 1 Interventional

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

NCT05642182
View directory record Official record
Conditions
Psoriasis
Interventions
SFA002
Drug
Lead sponsor
SFA Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Pompano Beach, Florida • Fargo, North Dakota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 24, 2026, 10:15 AM EDT
Not listed Phase 2Phase 3 Interventional

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

NCT05637879
View directory record Official record
Conditions
PTSD
Interventions
Glecaprevir/pibrentasvir, Placebo
Drug · Other
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
19 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

NCT02836496
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

Testosterone Replacement in Men With Diabetes and Obesity

NCT01127659
View directory record Official record
Conditions
Hypogonadism
Interventions
testosterone, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
30 Years to 65 Years · Male only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 24, 2026, 10:15 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Mixed-Methods Evaluation of Short-, Medium-, and Long-Term Outcomes Following Hip Treatment

NCT06891196
View directory record Official record
Conditions
Hip Dysplasia, Legg-Calvâe-Perthes Disease, Avascular Necrosis of Hip
Interventions
Long-term Follow-up Surveys
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease

NCT02462603
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PTC-589
Drug
Lead sponsor
Edison Pharmaceuticals Inc
Industry
Eligibility
21 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Not applicable Interventional

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

NCT00826059
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Active Sphenopalatine Ganglion (SPG) Stimulation, Sham Sphenopalatine Ganglion (SPG) Stimulation
Device
Lead sponsor
BrainsGate
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
7
States / cities
Sarasota, Florida • Winfield, Illinois • Greensboro, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 24, 2026, 10:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multimodal Investigation of Neural Plasticity

NCT06453980
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
sham tDCS, active tDCS
Device
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

NCT03891862
View directory record Official record
Conditions
Tardive Dyskinesia (TD)
Interventions
Valbenazine, Placebo oral capsule
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
42
States / cities
Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Early Phase 1 Interventional Results available

Psilocybin Cancer Anxiety Study

NCT00957359
View directory record Official record
Conditions
Cancer
Interventions
Psilocybin, Niacin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 76 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 24, 2026, 10:15 AM EDT
Recruiting Not applicable Interventional

Vibratory Genital Nerve Stimulation (vGNS) to Treat Female Sexual Dysfunction (FSD) After Spinal Cord Injury (SCI)

NCT07870642
View directory record Official record
Conditions
Spinal Cord Injury, Sexual Dysfunction Female
Interventions
Vibratory genital nerve stimulation
Device
Lead sponsor
Samuel Cramer
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

NCT03455270
View directory record Official record
Conditions
Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer
Interventions
G1T48, Palbociclib
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Beverly Hills, California • Stanford, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

NCT01301066
View directory record Official record
Conditions
Dyslipidemia
Interventions
Pitavastatin, Pravastatin
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
35
States / cities
Phoenix, Arizona • Beverly Hills, California • Costa Mesa, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 24, 2026, 10:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

NCT06104280
View directory record Official record
Conditions
Opioid Use Disorder, Sleep Disturbance
Interventions
Post-Illumination Pupillary Response (PIPR), Polysomnography, Multiple Sleep Latency Test, Ecological Momentary Assessments, Actigraphy, DLMO, Melatonin Suppression Test
Other · Behavioral · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Phase 2 Interventional

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

NCT01234779
View directory record Official record
Conditions
Schizophrenia
Interventions
bitopertin [RO4917838], olanzapine, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Children's Cognitive Function and Achievement Through Carotenoid Consumption

NCT05177679
View directory record Official record
Conditions
Cognitive Change, Achievement, Macular Pigmentation
Interventions
Active supplement, Placebo control
Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
8 Years to 10 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

NCT01185288
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
46
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee

NCT03291470
View directory record Official record
Conditions
Degenerative Osteoarthritis
Interventions
TG-C, Placebo Control
Biological
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
40 Years and older
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
27
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 24, 2026, 10:15 AM EDT
Not yet recruiting Phase 3 Interventional

A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer

NCT02448173
View directory record Official record
Conditions
Stage II Colon Cancer
Interventions
OncoVAX and Surgery, Surgery
Biological · Procedure
Lead sponsor
Vaccinogen Inc
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 24, 2026, 10:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diet, Exercise and Body Fat in 3-5 Year Olds

NCT00615641
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
3 Years to 5 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2010 · Synced Oct 24, 2026, 10:15 AM EDT
Completed Not applicable Interventional Results available

Isoenergetic High Intensity Interval Training and Moderate Intensity Training in Adults With Type I Diabetes

NCT04664205
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
High Intensity Interval Exercise, Moderate Intensity Continuous Exercise, Control
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 51 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 24, 2026, 10:15 AM EDT